{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T19:57:25Z","timestamp":1793649445681,"version":"4.5.1"},"reference-count":166,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T00:00:00Z","timestamp":1739923200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1007\/s40265-024-02138-w","type":"journal-article","created":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T23:51:15Z","timestamp":1739922675000},"page":"343-360","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":78,"title":["Treatment of Osteoporosis and Osteoarthritis in the Oldest Old"],"prefix":"10.1007","volume":"85","author":[{"given":"Nicholas","family":"Fuggle","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Laslop","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren\u00e9","family":"Rizzoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nasser","family":"Al-Daghri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Majed","family":"Alokail","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewa","family":"Balkowiec-Iskra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Beaudart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Bruy\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angie Botto-van","family":"Bemden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nansa","family":"Burlet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Etienne","family":"Cavalier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Cerreta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manju","family":"Chandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Cherubini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario Miguel Coelho","family":"da Silva Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philip","family":"Conaghan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernard","family":"Cortet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso Cruz","family":"Jentoft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth M.","family":"Curtis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"D\u2019Amelio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bess","family":"Dawson-Hughes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine M.","family":"Dennison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micka\u00ebl","family":"Hiligsmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Marc","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Maggi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radmila","family":"Matijevic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"McCloskey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Messina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Concepcion Prieto","family":"Yerro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00e9gis Pierre","family":"Radermecker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Rolland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Torre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Veronese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John A.","family":"Kanis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Yves","family":"Reginster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas C.","family":"Harvey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,2,19]]},"reference":[{"issue":"2","key":"2138_CR1","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/s00774-013-0531-0","volume":"32","author":"G-I Im","year":"2014","unstructured":"Im G-I, Kim M-K. The relationship between osteoarthritis and osteoporosis. J Bone Miner Metab. 2014;32(2):101\u20139.","journal-title":"J Bone Miner Metab"},{"issue":"9","key":"2138_CR2","doi-asserted-by":"publisher","first-page":"e508","DOI":"10.1016\/S2665-9913(23)00163-7","volume":"5","author":"JD Steinmetz","year":"2023","unstructured":"Steinmetz JD, et al. Global, regional, and national burden of osteoarthritis, 1990\u20132020 and projections to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet Rheumatol. 2023;5(9):e508\u201322.","journal-title":"Lancet Rheumatol"},{"issue":"9527","key":"2138_CR3","doi-asserted-by":"publisher","first-page":"2010","DOI":"10.1016\/S0140-6736(06)68891-0","volume":"367","author":"P Sambrook","year":"2006","unstructured":"Sambrook P, Cooper C. Osteoporosis. Lancet. 2006;367(9527):2010\u20138.","journal-title":"Lancet"},{"issue":"1","key":"2138_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1007\/s00198-023-06907-3","volume":"35","author":"JN Feng","year":"2024","unstructured":"Feng JN, et al. Global burden of hip fracture: the Global Burden of Disease Study. Osteoporos Int. 2024;35(1):41\u201352.","journal-title":"Osteoporos Int"},{"issue":"1","key":"2138_CR5","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1159\/000272025","volume":"56","author":"M MacDonald","year":"2010","unstructured":"MacDonald M, et al. Distal and proximal resource influences on economic dependency among the oldest old. Gerontology. 2010;56(1):100\u20135.","journal-title":"Gerontology"},{"key":"2138_CR6","doi-asserted-by":"crossref","unstructured":"Ioakeim-Skoufa, I., et al., Multimorbidity Clusters in the Oldest Old: Results from the EpiChron Cohort. Int J Environ Res Public Health, 2022. 19(16).","DOI":"10.3390\/ijerph191610180"},{"issue":"1","key":"2138_CR7","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1146\/annurev.pa.32.040192.001415","volume":"32","author":"N Tumer","year":"1992","unstructured":"Tumer N, Scarpace PJ, Lowenthal DT. Geriatric pharmacology: basic and clinical considerations. Annu Rev Pharmacol Toxicol. 1992;32(1):271\u2013302.","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"3","key":"2138_CR8","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1002\/cpt.2793","volume":"113","author":"F Cerreta","year":"2023","unstructured":"Cerreta F, Vu\u010di\u0107 K, Laslop A. Assessing medicines for use in the geriatric population. Clin Pharmacol Ther. 2023;113(3):536\u201340.","journal-title":"Clin Pharmacol Ther"},{"key":"2138_CR9","doi-asserted-by":"crossref","unstructured":"Cerreta F, et al. Medicines for an aging population: the EMA perspective and policies. J Am Geriatr Soc. 2024.","DOI":"10.1111\/jgs.18953"},{"key":"2138_CR10","doi-asserted-by":"publisher","first-page":"3637","DOI":"10.1007\/978-3-030-22009-9_1121","volume-title":"Encyclopedia of gerontology and population aging","author":"Q Wu","year":"2021","unstructured":"Wu Q, Gu D. Oldest-old adults. In: Gu D, Dupre ME, editors. Encyclopedia of gerontology and population aging. Cham: Springer International Publishing; 2021;72(9):2921\u20137."},{"key":"2138_CR11","unstructured":"Agency EM. Studies in Support of Special Populations: Geriatrics (CPMP\/ICH\/379\/95). 1994."},{"issue":"1","key":"2138_CR12","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1186\/s12875-020-01128-7","volume":"21","author":"E Escourrou","year":"2020","unstructured":"Escourrou E, et al. Cognitive, functional, physical, and nutritional status of the oldest old encountered in primary care: a systematic review. BMC Fam Pract. 2020;21(1):58.","journal-title":"BMC Fam Pract"},{"issue":"2","key":"2138_CR13","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1097\/WAD.0000000000000260","volume":"33","author":"ZA Melikyan","year":"2019","unstructured":"Melikyan ZA, et al. Recruiting the oldest-old for clinical research. Alzheimer Dis Assoc Disord. 2019;33(2):160\u20132.","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"3","key":"2138_CR14","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1017\/S0144686X00001677","volume":"14","author":"P Laslett","year":"1994","unstructured":"Laslett P. The Third Age, The Fourth Age and The Future. Ageing Soc. 1994;14(3):436\u201347.","journal-title":"Ageing Soc"},{"key":"2138_CR15","doi-asserted-by":"crossref","unstructured":"Vaiserman A, Krasnienkov D. Telomere length as a marker of biological age: state-of-the-art, open issues, and future perspectives. Front Genet. 2021;11.","DOI":"10.3389\/fgene.2020.630186"},{"issue":"2","key":"2138_CR16","doi-asserted-by":"publisher","first-page":"303","DOI":"10.18632\/aging.101684","volume":"11","author":"AT Lu","year":"2019","unstructured":"Lu AT, et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. Aging (Albany NY). 2019;11(2):303\u201327.","journal-title":"Aging (Albany NY)"},{"issue":"4","key":"2138_CR17","doi-asserted-by":"publisher","first-page":"573","DOI":"10.18632\/aging.101414","volume":"10","author":"ME Levine","year":"2018","unstructured":"Levine ME, et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging (Albany NY). 2018;10(4):573\u201391.","journal-title":"Aging (Albany NY)"},{"issue":"12","key":"2138_CR18","doi-asserted-by":"publisher","first-page":"3155","DOI":"10.1007\/s40520-022-02216-7","volume":"34","author":"JA Kanis","year":"2022","unstructured":"Kanis JA, et al. Intervention thresholds and diagnostic thresholds in the management of osteoporosis. Aging Clin Exp Res. 2022;34(12):3155\u20137.","journal-title":"Aging Clin Exp Res"},{"issue":"2","key":"2138_CR19","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.injury.2022.12.008","volume":"54","author":"S Haleem","year":"2023","unstructured":"Haleem S, et al. Mortality following hip fracture: Trends and geographical variations over the last SIXTY years. Injury. 2023;54(2):620\u20139.","journal-title":"Injury"},{"issue":"1","key":"2138_CR20","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.jocd.2015.08.004","volume":"19","author":"JT Schousboe","year":"2016","unstructured":"Schousboe JT. Epidemiology of Vertebral Fractures. J Clin Densitom. 2016;19(1):8\u201322.","journal-title":"J Clin Densitom"},{"issue":"4","key":"2138_CR21","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1007\/s00198-008-0685-0","volume":"20","author":"H Hagino","year":"2009","unstructured":"Hagino H, et al. Recent trends in the incidence and lifetime risk of hip fracture in Tottori. Japan Osteoporos Int. 2009;20(4):543\u20138.","journal-title":"Japan. Osteoporos Int"},{"issue":"1","key":"2138_CR22","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1007\/s11657-020-00823-3","volume":"15","author":"H Hagino","year":"2020","unstructured":"Hagino H, et al. Recent trends in the incidence of hip fracture in Tottori Prefecture, Japan: changes over 32 years. Arch Osteoporos. 2020;15(1):152.","journal-title":"Arch Osteoporos"},{"issue":"8","key":"2138_CR23","doi-asserted-by":"publisher","first-page":"1609","DOI":"10.1007\/s40520-023-02445-4","volume":"35","author":"R Guti\u00e9rrez-Gonz\u00e1lez","year":"2023","unstructured":"Guti\u00e9rrez-Gonz\u00e1lez R, Royuela A, Zamarron A. Survival following vertebral compression fractures in population over 65 years old. Aging Clin Exp Res. 2023;35(8):1609\u201317.","journal-title":"Aging Clin Exp Res"},{"key":"2138_CR24","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/1471-2318-11-37","volume":"11","author":"E Castronuovo","year":"2011","unstructured":"Castronuovo E, et al. Early and late mortality in elderly patients after hip fracture: a cohort study using administrative health databases in the Lazio region. Italy BMC Geriatr. 2011;11:37.","journal-title":"Italy. BMC Geriatr"},{"issue":"1","key":"2138_CR25","doi-asserted-by":"publisher","first-page":"728","DOI":"10.1186\/s12877-023-04430-y","volume":"23","author":"Q Li","year":"2023","unstructured":"Li Q, et al. Age-dependent gender differences in the diagnosis and treatment of osteoporosis during hospitalization in patients with fragility fractures. BMC Geriatr. 2023;23(1):728.","journal-title":"BMC Geriatr"},{"issue":"1","key":"2138_CR26","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/s00198-014-2837-8","volume":"26","author":"R Duncan","year":"2015","unstructured":"Duncan R, et al. Magnitude of fragility fracture risk in the very old\u2013are we meeting their needs? The Newcastle 85+ Study. Osteoporos Int. 2015;26(1):123\u201330.","journal-title":"Osteoporos Int"},{"issue":"1","key":"2138_CR27","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s11657-020-00871-9","volume":"16","author":"JA Kanis","year":"2021","unstructured":"Kanis JA, et al. SCOPE 2021: a new scorecard for osteoporosis in Europe. Arch Osteoporos. 2021;16(1):82.","journal-title":"Arch Osteoporos"},{"issue":"2","key":"2138_CR28","doi-asserted-by":"publisher","first-page":"168","DOI":"10.14283\/jfa.2021.4","volume":"10","author":"Y Rolland","year":"2021","unstructured":"Rolland Y, et al. Osteoporosis in frail older adults: recommendations for research from the ICFSR Task Force 2020. J Frailty Aging. 2021;10(2):168\u201375.","journal-title":"J Frailty Aging"},{"issue":"1","key":"2138_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s40520-024-02714-w","volume":"36","author":"G Herrero-Beaumont","year":"2024","unstructured":"Herrero-Beaumont G, et al. Systemic osteoarthritis: the difficulty of categorically naming a continuous condition. Aging Clin Exp Res. 2024;36(1):45.","journal-title":"Aging Clin Exp Res"},{"issue":"8","key":"2138_CR30","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1002\/art.1780290816","volume":"29","author":"R Altman","year":"1986","unstructured":"Altman R, et al. Development of criteria for the classification and reporting of osteoarthritis. Classification of osteoarthritis of the knee. Diagnostic and Therapeutic Criteria Committee of the American Rheumatism Association. Arthritis Rheum. 1986;29(8):1039\u201349.","journal-title":"Arthritis Rheum"},{"issue":"4","key":"2138_CR31","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1136\/ard.16.4.494","volume":"16","author":"JH Kellgren","year":"1957","unstructured":"Kellgren JH, Lawrence JS. Radiological assessment of osteo-arthrosis. Ann Rheum Dis. 1957;16(4):494\u2013502.","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"2138_CR32","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1002\/ejp.2236","volume":"28","author":"JA Lozano-Meca","year":"2024","unstructured":"Lozano-Meca JA, Gacto-S\u00e1nchez M, Montilla-Herrador J. Movement-evoked pain is not associated with pain at rest or physical function in knee osteoarthritis. Eur J Pain. 2024;28(6):987\u201396.","journal-title":"Eur J Pain"},{"issue":"1","key":"2138_CR33","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-031734","volume":"10","author":"D Spitaels","year":"2020","unstructured":"Spitaels D, et al. Epidemiology of knee osteoarthritis in general practice: a registry-based study. BMJ Open. 2020;10(1): e031734.","journal-title":"BMJ Open"},{"issue":"6","key":"2138_CR34","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/j.joca.2020.03.004","volume":"28","author":"S Swain","year":"2020","unstructured":"Swain S, et al. Trends in incidence and prevalence of osteoarthritis in the United Kingdom: findings from the Clinical Practice Research Datalink (CPRD). Osteoarthritis Cartilage. 2020;28(6):792\u2013801.","journal-title":"Osteoarthritis Cartilage"},{"issue":"11","key":"2138_CR35","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-033334","volume":"9","author":"DA Marshall","year":"2019","unstructured":"Marshall DA, et al. Existing comorbidities in people with osteoarthritis: a retrospective analysis of a population-based cohort in Alberta, Canada. BMJ Open. 2019;9(11): e033334.","journal-title":"BMJ Open"},{"issue":"4","key":"2138_CR36","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1586\/17512433.2014.922864","volume":"7","author":"P Crome","year":"2014","unstructured":"Crome P, Cherubini A, Oristrell J. The PREDICT (increasing the participation of the elderly in clinical trials) study: the charter and beyond. Expert Rev Clin Pharmacol. 2014;7(4):457\u201368.","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"2","key":"2138_CR37","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s41999-024-00938-7","volume":"15","author":"A Ungar","year":"2024","unstructured":"Ungar A, et al. Carta of Florence against ageism. No place for ageism in health care. Eur Geriatr Med. 2024;15(2):285\u201390.","journal-title":"Eur Geriatr Med"},{"issue":"11","key":"2138_CR38","doi-asserted-by":"publisher","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","volume":"85","author":"DM Black","year":"2000","unstructured":"Black DM, et al. Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group. J Clin Endocrinol Metab. 2000;85(11):4118\u201324.","journal-title":"J Clin Endocrinol Metab"},{"key":"2138_CR39","doi-asserted-by":"crossref","unstructured":"Ensrud, K.E., et al., Correlates of kyphosis in older women. The Fracture Intervention Trial Research Group. J Am Geriatr Soc, 1997. 45(6): p. 682-7.","DOI":"10.1111\/j.1532-5415.1997.tb01470.x"},{"issue":"6","key":"2138_CR40","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1359\/JBMR.050104","volume":"20","author":"MC Hochberg","year":"2005","unstructured":"Hochberg MC, et al. Effect of alendronate on the age-specific incidence of symptomatic osteoporotic fractures. J Bone Miner Res. 2005;20(6):971\u20136.","journal-title":"J Bone Miner Res"},{"issue":"6","key":"2138_CR41","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1111\/joim.12678","volume":"282","author":"KF Axelsson","year":"2017","unstructured":"Axelsson KF, et al. Hip fracture risk and safety with alendronate treatment in the oldest-old. J Intern Med. 2017;282(6):546\u201359.","journal-title":"J Intern Med"},{"issue":"11","key":"2138_CR42","doi-asserted-by":"publisher","first-page":"2625","DOI":"10.1007\/s40520-022-02272-z","volume":"34","author":"N Fuggle","year":"2022","unstructured":"Fuggle N, et al. Novel formulations of oral bisphosphonates in the treatment of osteoporosis. Aging Clin Exp Res. 2022;34(11):2625\u201334.","journal-title":"Aging Clin Exp Res"},{"issue":"5","key":"2138_CR43","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1056\/NEJM200102013440503","volume":"344","author":"MR McClung","year":"2001","unstructured":"McClung MR, et al. Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group. N Engl J Med. 2001;344(5):333\u201340.","journal-title":"N Engl J Med"},{"issue":"1","key":"2138_CR44","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1007\/s001980050010","volume":"11","author":"J Reginster","year":"2000","unstructured":"Reginster J, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. Osteoporos Int. 2000;11(1):83\u201391.","journal-title":"Osteoporos Int"},{"key":"2138_CR45","doi-asserted-by":"crossref","unstructured":"Harris, S.T., et al., Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. Jama, 1999. 282(14): p. 1344-52.","DOI":"10.1001\/jama.282.14.1344"},{"issue":"11","key":"2138_CR46","doi-asserted-by":"publisher","first-page":"1832","DOI":"10.1111\/j.1532-5415.2004.52506.x","volume":"52","author":"S Boonen","year":"2004","unstructured":"Boonen S, et al. Safety and efficacy of risedronate in reducing fracture risk in osteoporotic women aged 80 and older: implications for the use of antiresorptive agents in the old and oldest old. J Am Geriatr Soc. 2004;52(11):1832\u20139.","journal-title":"J Am Geriatr Soc"},{"issue":"18","key":"2138_CR47","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1056\/NEJMoa067312","volume":"356","author":"DM Black","year":"2007","unstructured":"Black DM, et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med. 2007;356(18):1809\u201322.","journal-title":"N Engl J Med"},{"issue":"2","key":"2138_CR48","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1111\/j.1532-5415.2009.02673.x","volume":"58","author":"S Boonen","year":"2010","unstructured":"Boonen S, et al. Efficacy and safety of a once-yearly intravenous zoledronic acid 5 mg for fracture prevention in elderly postmenopausal women with osteoporosis aged 75 and older. J Am Geriatr Soc. 2010;58(2):292\u20139.","journal-title":"J Am Geriatr Soc"},{"issue":"18","key":"2138_CR49","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1056\/NEJMoa074941","volume":"357","author":"KW Lyles","year":"2007","unstructured":"Lyles KW, et al. Zoledronic acid and clinical fractures and mortality after hip fracture. N Engl J Med. 2007;357(18):1799\u2013809.","journal-title":"N Engl J Med"},{"issue":"15","key":"2138_CR50","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1007\/s40265-020-01364-2","volume":"80","author":"NR Fuggle","year":"2020","unstructured":"Fuggle NR, et al. Assessment of Cardiovascular Safety of Anti-Osteoporosis Drugs. Drugs. 2020;80(15):1537\u201352.","journal-title":"Drugs"},{"issue":"7","key":"2138_CR51","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/S2213-8587(17)30138-9","volume":"5","author":"HG Bone","year":"2017","unstructured":"Bone HG, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol. 2017;5(7):513\u201323.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"11","key":"2138_CR52","doi-asserted-by":"publisher","first-page":"4483","DOI":"10.1210\/jc.2013-1597","volume":"98","author":"HG Bone","year":"2013","unstructured":"Bone HG, et al. The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension. J Clin Endocrinol Metab. 2013;98(11):4483\u201392.","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"2138_CR53","doi-asserted-by":"publisher","first-page":"1727","DOI":"10.1210\/jc.2010-2784","volume":"96","author":"S Boonen","year":"2011","unstructured":"Boonen S, et al. Treatment with denosumab reduces the incidence of new vertebral and hip fractures in postmenopausal women at high risk. J Clin Endocrinol Metab. 2011;96(6):1727\u201336.","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"2138_CR54","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1002\/jbmr.4705","volume":"37","author":"F Cosman","year":"2022","unstructured":"Cosman F, et al. Multiple Vertebral Fractures After Denosumab Discontinuation: FREEDOM and FREEDOM Extension Trials Additional Post Hoc Analyses. J Bone Miner Res. 2022;37(11):2112\u201320.","journal-title":"J Bone Miner Res"},{"issue":"1","key":"2138_CR55","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1002\/jbmr.536","volume":"27","author":"MR McClung","year":"2012","unstructured":"McClung MR, et al. Effect of denosumab treatment on the risk of fractures in subgroups of women with postmenopausal osteoporosis. J Bone Miner Res. 2012;27(1):211\u20138.","journal-title":"J Bone Miner Res"},{"issue":"7","key":"2138_CR56","doi-asserted-by":"publisher","first-page":"1465","DOI":"10.1007\/s00198-019-04947-2","volume":"30","author":"J Reginster","year":"2019","unstructured":"Reginster J, et al. Abaloparatide for risk reduction of nonvertebral and vertebral fractures in postmenopausal women with osteoporosis: a network meta-analysis. Osteoporos Int. 2019;30(7):1465\u201373.","journal-title":"Osteoporos Int"},{"key":"2138_CR57","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-068033","volume":"381","author":"MN H\u00e4ndel","year":"2023","unstructured":"H\u00e4ndel MN, et al. Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials. BMJ. 2023;381: e068033.","journal-title":"BMJ"},{"issue":"19","key":"2138_CR58","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","volume":"344","author":"RM Neer","year":"2001","unstructured":"Neer RM, et al. Effect of parathyroid hormone (1\u201334) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344(19):1434\u201341.","journal-title":"N Engl J Med"},{"issue":"5","key":"2138_CR59","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1111\/j.1532-5415.2006.00695.x","volume":"54","author":"S Boonen","year":"2006","unstructured":"Boonen S, et al. Safety and efficacy of teriparatide in elderly women with established osteoporosis: bone anabolic therapy from a geriatric perspective. J Am Geriatr Soc. 2006;54(5):782\u20139.","journal-title":"J Am Geriatr Soc"},{"issue":"11","key":"2138_CR60","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.1080\/03007995.2020.1824897","volume":"36","author":"PD Miller","year":"2020","unstructured":"Miller PD, et al. Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis. Curr Med Res Opin. 2020;36(11):1861\u201372.","journal-title":"Curr Med Res Opin"},{"issue":"7","key":"2138_CR61","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1001\/jama.2016.11136","volume":"316","author":"PD Miller","year":"2016","unstructured":"Miller PD, et al. Effect of abaloparatide vs placebo on new vertebral fractures in postmenopausal women with osteoporosis: a randomized clinical trial. JAMA. 2016;316(7):722\u201333.","journal-title":"JAMA"},{"issue":"7","key":"2138_CR62","doi-asserted-by":"publisher","first-page":"767","DOI":"10.1097\/GME.0000000000001080","volume":"25","author":"MR McClung","year":"2018","unstructured":"McClung MR, et al. Effects of abaloparatide on bone mineral density and risk of fracture in postmenopausal women aged 80 years or older with osteoporosis. Menopause. 2018;25(7):767\u201371.","journal-title":"Menopause"},{"key":"2138_CR63","unstructured":"Agency EM. Eladynos (abaloparatide) EMA\/852056\/2022. 2022."},{"issue":"8","key":"2138_CR64","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1007\/s00198-022-06413-y","volume":"33","author":"F Cosman","year":"2022","unstructured":"Cosman F, et al. Comparative effectiveness and cardiovascular safety of abaloparatide and teriparatide in postmenopausal women new to anabolic therapy: a US administrative claims database study. Osteoporos Int. 2022;33(8):1703\u201314.","journal-title":"Osteoporos Int"},{"issue":"15","key":"2138_CR65","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1056\/NEJMoa1708322","volume":"377","author":"KG Saag","year":"2017","unstructured":"Saag KG, et al. Romosozumab or alendronate for fracture prevention in women with osteoporosis. N Engl J Med. 2017;377(15):1417\u201327.","journal-title":"N Engl J Med"},{"issue":"8","key":"2138_CR66","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2106\/JBJS.19.00790","volume":"102","author":"EH Schemitsch","year":"2020","unstructured":"Schemitsch EH, et al. A randomized, placebo-controlled study of romosozumab for the treatment of hip fractures. J Bone Joint Surg Am. 2020;102(8):693\u2013702.","journal-title":"J Bone Joint Surg Am"},{"issue":"16","key":"2138_CR67","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1056\/NEJMoa1607948","volume":"375","author":"F Cosman","year":"2016","unstructured":"Cosman F, et al. Romosozumab treatment in postmenopausal women with osteoporosis. N Engl J Med. 2016;375(16):1532\u201343.","journal-title":"N Engl J Med"},{"issue":"10102","key":"2138_CR68","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.1016\/S0140-6736(17)31613-6","volume":"390","author":"BL Langdahl","year":"2017","unstructured":"Langdahl BL, et al. Romosozumab (sclerostin monoclonal antibody) versus teriparatide in postmenopausal women with osteoporosis transitioning from oral bisphosphonate therapy: a randomised, open-label, phase 3 trial. Lancet. 2017;390(10102):1585\u201394.","journal-title":"Lancet"},{"issue":"5","key":"2138_CR69","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1056\/NEJMoa1305224","volume":"370","author":"MR McClung","year":"2014","unstructured":"McClung MR, et al. Romosozumab in postmenopausal women with low bone mineral density. N Engl J Med. 2014;370(5):412\u201320.","journal-title":"N Engl J Med"},{"key":"2138_CR70","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.bone.2017.07.005","volume":"103","author":"H Ishibashi","year":"2017","unstructured":"Ishibashi H, et al. Romosozumab increases bone mineral density in postmenopausal Japanese women with osteoporosis: a phase 2 study. Bone. 2017;103:209\u201315.","journal-title":"Bone"},{"issue":"9","key":"2138_CR71","doi-asserted-by":"publisher","first-page":"3183","DOI":"10.1210\/jc.2017-02163","volume":"103","author":"EM Lewiecki","year":"2018","unstructured":"Lewiecki EM, et al. A Phase III Randomized Placebo-Controlled Trial to Evaluate Efficacy and Safety of Romosozumab in Men With Osteoporosis. J Clin Endocrinol Metab. 2018;103(9):3183\u201393.","journal-title":"J Clin Endocrinol Metab"},{"key":"2138_CR72","doi-asserted-by":"publisher","first-page":"115121","DOI":"10.1016\/j.bone.2019.115121","volume":"130","author":"F Lv","year":"2020","unstructured":"Lv F, et al. Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis. Bone. 2020;130:115121\u2013115121.","journal-title":"Bone"},{"key":"2138_CR73","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2022.116610","volume":"167","author":"AH Seeto","year":"2023","unstructured":"Seeto AH, et al. Evidence for the cardiovascular effects of osteoporosis treatments in randomized trials of post-menopausal women: a systematic review and Bayesian network meta-analysis. Bone. 2023;167: 116610.","journal-title":"Bone"},{"key":"2138_CR74","doi-asserted-by":"crossref","unstructured":"Vestergaard Kvist A, et al. Cardiovascular safety profile of romosozumab: a pharmacovigilance analysis of the US Food and Drug Administration Adverse Event Reporting System (FAERS). J Clin Med. 2021;10(8).","DOI":"10.3390\/jcm10081660"},{"key":"2138_CR75","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j2099","volume":"357","author":"J Hippisley-Cox","year":"2017","unstructured":"Hippisley-Cox J, Coupland C, Brindle P. Development and validation of QRISK3 risk prediction algorithms to estimate future risk of cardiovascular disease: prospective cohort study. BMJ. 2017;357: j2099.","journal-title":"BMJ"},{"key":"2138_CR76","doi-asserted-by":"publisher","unstructured":"Tabatabai L, et al. Comparative effectiveness of abaloparatide and teriparatide in women 50 years of age and older: update of a real-world retrospective analysis. Endocr Pract. 2024:S1530-891X(24):00827-9. https:\/\/doi.org\/10.1016\/j.eprac.2024.10.017. PMID: 39551187","DOI":"10.1016\/j.eprac.2024.10.017"},{"issue":"10122","key":"2138_CR77","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0140-6736(17)32640-5","volume":"391","author":"L Shepstone","year":"2018","unstructured":"Shepstone L, et al. Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. Lancet. 2018;391(10122):741\u20137.","journal-title":"Lancet"},{"issue":"8","key":"2138_CR78","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1007\/s00198-020-05372-6","volume":"31","author":"E S\u00f6reskog","year":"2020","unstructured":"S\u00f6reskog E, et al. Long-term cost-effectiveness of screening for fracture risk in a UK primary care setting: the SCOOP study. Osteoporos Int. 2020;31(8):1499\u2013506.","journal-title":"Osteoporos Int"},{"key":"2138_CR79","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2020.115833","volume":"144","author":"NR Fuggle","year":"2021","unstructured":"Fuggle NR, et al. The treatment gap: The missed opportunities for osteoporosis therapy. Bone. 2021;144: 115833.","journal-title":"Bone"},{"issue":"6","key":"2138_CR80","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s00198-018-4411-2","volume":"29","author":"CH Wu","year":"2018","unstructured":"Wu CH, et al. Economic impact and cost-effectiveness of fracture liaison services: a systematic review of the literature. Osteoporos Int. 2018;29(6):1227\u201342.","journal-title":"Osteoporos Int"},{"key":"2138_CR81","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.bone.2018.03.018","volume":"111","author":"CH Wu","year":"2018","unstructured":"Wu CH, et al. Fracture liaison services improve outcomes of patients with osteoporosis-related fractures: a systematic literature review and meta-analysis. Bone. 2018;111:92\u2013100.","journal-title":"Bone"},{"issue":"1","key":"2138_CR82","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1007\/s40520-024-02761-3","volume":"36","author":"D Gonz\u00e1lez-Quevedo","year":"2024","unstructured":"Gonz\u00e1lez-Quevedo D, et al. Secondary osteoporosis prevention: three-year outcomes from a Fracture Liaison Service in elderly hip fracture patients. Aging Clin Exp Res. 2024;36(1):103.","journal-title":"Aging Clin Exp Res"},{"issue":"3","key":"2138_CR83","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.semarthrit.2019.04.008","volume":"49","author":"O Bruy\u00e8re","year":"2019","unstructured":"Bruy\u00e8re O, et al. An updated algorithm recommendation for the management of knee osteoarthritis from the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). Semin Arthritis Rheum. 2019;49(3):337\u201350.","journal-title":"Semin Arthritis Rheum"},{"issue":"2","key":"2138_CR84","doi-asserted-by":"publisher","DOI":"10.2106\/JBJS.RVW.17.00077","volume":"6","author":"BPD Murphy","year":"2018","unstructured":"Murphy BPD, Dowsey MM, Choong PFM. The Impact of advanced age on the outcomes of primary total hip and knee arthroplasty for osteoarthritis: a systematic review. JBJS Rev. 2018;6(2): e6.","journal-title":"JBJS Rev"},{"issue":"7","key":"2138_CR85","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1007\/s11606-021-06755-z","volume":"36","author":"W Yang","year":"2021","unstructured":"Yang W, et al. The efficacy and safety of disease-modifying osteoarthritis drugs for knee and hip osteoarthritis\u2014a systematic review and network meta-analysis. J Gen Intern Med. 2021;36(7):2085\u201393.","journal-title":"J Gen Intern Med"},{"issue":"2","key":"2138_CR86","first-page":"Cd002946","volume":"2005","author":"TE Towheed","year":"2005","unstructured":"Towheed TE, et al. Glucosamine therapy for treating osteoarthritis. Cochrane Database Syst Rev. 2005;2005(2):Cd002946.","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"2138_CR87","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212251","volume":"77","author":"JL Reginster","year":"2018","unstructured":"Reginster JL, Bruyere O, Cooper C. Different glucosamine sulfate products generate different outcomes on osteoarthritis symptoms. Ann Rheum Dis. 2018;77(7): e39.","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"2138_CR88","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212460","volume":"77","author":"JY Reginster","year":"2018","unstructured":"Reginster JY. Differentiation between various Chondroitin sulfate formulations in symptomatic knee osteoarthritis. Ann Rheum Dis. 2018;77(8): e55.","journal-title":"Ann Rheum Dis"},{"issue":"9252","key":"2138_CR89","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1016\/S0140-6736(00)03610-2","volume":"357","author":"JY Reginster","year":"2001","unstructured":"Reginster JY, et al. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomised, placebo-controlled clinical trial. Lancet. 2001;357(9252):251\u20136.","journal-title":"Lancet"},{"issue":"18","key":"2138_CR90","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1001\/archinte.162.18.2113","volume":"162","author":"K Pavelk\u00e1","year":"2002","unstructured":"Pavelk\u00e1 K, et al. Glucosamine sulfate use and delay of progression of knee osteoarthritis: a 3-year, randomized, placebo-controlled, double-blind study. Arch Intern Med. 2002;162(18):2113\u201323.","journal-title":"Arch Intern Med"},{"key":"2138_CR91","doi-asserted-by":"publisher","first-page":"69","DOI":"10.2174\/1874312901105010069","volume":"5","author":"R Palma Dos Reis","year":"2011","unstructured":"Palma Dos Reis R, et al. Crystalline glucosamine sulfate in the treatment of osteoarthritis: evidence of long-term cardiovascular safety from clinical trials. Open Rheumatol J. 2011;5:69\u201377.","journal-title":"Open Rheumatol J"},{"issue":"Suppl 1","key":"2138_CR92","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s40266-019-00662-z","volume":"36","author":"G Honvo","year":"2019","unstructured":"Honvo G, et al. Safety of Symptomatic Slow-Acting Drugs for Osteoarthritis: Outcomes of a Systematic Review and Meta-Analysis. Drugs Aging. 2019;36(Suppl 1):65\u201399.","journal-title":"Drugs Aging"},{"issue":"5","key":"2138_CR93","doi-asserted-by":"publisher","first-page":"R106","DOI":"10.1186\/ar4286","volume":"15","author":"SR Kingsbury","year":"2013","unstructured":"Kingsbury SR, et al. How do people with knee osteoarthritis use osteoarthritis pain medications and does this change over time? Data from the Osteoarthritis Initiative. Arthritis Res Ther. 2013;15(5):R106.","journal-title":"Arthritis Res Ther"},{"issue":"7","key":"2138_CR94","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1097\/RHU.0000000000000853","volume":"25","author":"JJ van den Driest","year":"2019","unstructured":"van den Driest JJ, et al. Analgesic use in dutch patients with osteoarthritis: frequent but low doses. J Clin Rheumatol. 2019;25(7):297\u2013303.","journal-title":"J Clin Rheumatol"},{"issue":"3","key":"2138_CR95","doi-asserted-by":"publisher","first-page":"627","DOI":"10.5114\/aoms.2020.92894","volume":"16","author":"YL Huang","year":"2020","unstructured":"Huang YL, et al. Chronic pain and use of analgesics in the elderly: a nationwide population-based study. Arch Med Sci. 2020;16(3):627\u201334.","journal-title":"Arch Med Sci"},{"issue":"4","key":"2138_CR96","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1007\/s40266-019-00742-0","volume":"37","author":"AA Al-Qurain","year":"2020","unstructured":"Al-Qurain AA, et al. Prevalence and factors associated with analgesic prescribing in poly-medicated elderly patients. Drugs Aging. 2020;37(4):291\u2013300.","journal-title":"Drugs Aging"},{"issue":"2","key":"2138_CR97","first-page":"Cd013273","volume":"2","author":"AO Leopoldino","year":"2019","unstructured":"Leopoldino AO, et al. Paracetamol versus placebo for knee and hip osteoarthritis. Cochrane Database Syst Rev. 2019;2(2):Cd013273.","journal-title":"Cochrane Database Syst Rev"},{"issue":"9","key":"2138_CR98","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.joca.2021.06.004","volume":"29","author":"C Zeng","year":"2021","unstructured":"Zeng C, et al. Comparative efficacy and safety of acetaminophen, topical and oral non-steroidal anti-inflammatory drugs for knee osteoarthritis: evidence from a network meta-analysis of randomized controlled trials and real-world data. Osteoarthr Cartil. 2021;29(9):1242\u201351.","journal-title":"Osteoarthr Cartil"},{"key":"2138_CR99","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2321","volume":"375","author":"BR da Costa","year":"2021","unstructured":"da Costa BR, et al. Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: network meta-analysis. BMJ. 2021;375: n2321.","journal-title":"BMJ"},{"key":"2138_CR100","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.h1225","volume":"350","author":"GC Machado","year":"2015","unstructured":"Machado GC, et al. Efficacy and safety of paracetamol for spinal pain and osteoarthritis: systematic review and meta-analysis of randomised placebo controlled trials. BMJ. 2015;350: h1225.","journal-title":"BMJ"},{"issue":"4","key":"2138_CR101","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1111\/j.1572-0241.2008.01811.x","volume":"103","author":"E Rahme","year":"2008","unstructured":"Rahme E, et al. Hospitalizations for upper and lower GI events associated with traditional NSAIDs and acetaminophen among the elderly in Quebec. Canada Am J Gastroenterol. 2008;103(4):872\u201382.","journal-title":"Canada. Am J Gastroenterol"},{"issue":"11","key":"2138_CR102","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1002\/pds.3617","volume":"23","author":"FJ de Abajo","year":"2014","unstructured":"de Abajo FJ, et al. Risk of nonfatal acute myocardial infarction associated with non-steroidal antiinflammatory drugs, non-narcotic analgesics and other drugs used in osteoarthritis: a nested case-control study. Pharmacoepidemiol Drug Saf. 2014;23(11):1128\u201338.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"2138_CR103","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s12931-022-02010-z","volume":"23","author":"TL Kelly","year":"2022","unstructured":"Kelly TL, et al. The association between exacerbation of chronic obstructive pulmonary disease and timing of paracetamol use: a cohort study in elderly Australians. Respir Res. 2022;23(1):80.","journal-title":"Respir Res"},{"issue":"2","key":"2138_CR104","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-068220","volume":"13","author":"M Endo","year":"2023","unstructured":"Endo M, et al. Protocol for the RETHINK study: a randomised, double-blind, parallel-group, non-inferiority clinical trial comparing acetaminophen and NSAIDs for treatment of chronic pain in elderly patients with osteoarthritis of the hip and knee. BMJ Open. 2023;13(2): e068220.","journal-title":"BMJ Open"},{"issue":"1","key":"2138_CR105","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1038\/s41584-020-00523-9","volume":"17","author":"NK Arden","year":"2021","unstructured":"Arden NK, et al. Non-surgical management of knee osteoarthritis: comparison of ESCEO and OARSI 2019 guidelines. Nat Rev Rheumatol. 2021;17(1):59\u201366.","journal-title":"Nat Rev Rheumatol"},{"issue":"7","key":"2138_CR106","doi-asserted-by":"publisher","first-page":"603","DOI":"10.1007\/s40266-018-0559-x","volume":"35","author":"P Mian","year":"2018","unstructured":"Mian P, et al. Paracetamol in older people: towards evidence-based dosing? Drugs Aging. 2018;35(7):603\u201324.","journal-title":"Drugs Aging"},{"issue":"2","key":"2138_CR107","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1093\/ehjcvp\/pvv054","volume":"2","author":"M Schmidt","year":"2016","unstructured":"Schmidt M, et al. Cardiovascular safety of non-aspirin non-steroidal anti-inflammatory drugs: review and position paper by the working group for Cardiovascular Pharmacotherapy of the European Society of Cardiology. Eur Heart J Cardiovasc Pharmacother. 2016;2(2):108\u201318.","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"Suppl 1","key":"2138_CR108","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s40266-019-00664-x","volume":"36","author":"E Curtis","year":"2019","unstructured":"Curtis E, et al. Safety of cyclooxygenase-2 inhibitors in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs Aging. 2019;36(Suppl 1):25\u201344.","journal-title":"Drugs Aging"},{"issue":"1","key":"2138_CR109","doi-asserted-by":"publisher","first-page":"143","DOI":"10.14336\/AD.2017.0306","volume":"9","author":"S Wongrakpanich","year":"2018","unstructured":"Wongrakpanich S, et al. A comprehensive review of non-steroidal anti-inflammatory drug use in the elderly. Aging Dis. 2018;9(1):143\u201350.","journal-title":"Aging Dis"},{"issue":"Suppl 1","key":"2138_CR110","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s40266-019-00666-9","volume":"36","author":"N Fuggle","year":"2019","unstructured":"Fuggle N, et al. Safety of opioids in osteoarthritis: outcomes of a systematic review and meta-analysis. Drugs Aging. 2019;36(Suppl 1):129\u201343.","journal-title":"Drugs Aging"},{"issue":"26","key":"2138_CR111","doi-asserted-by":"publisher","first-page":"2519","DOI":"10.1056\/NEJMoa1611593","volume":"375","author":"SE Nissen","year":"2016","unstructured":"Nissen SE, et al. Cardiovascular Safety of Celecoxib, Naproxen, or Ibuprofen for Arthritis. N Engl J Med. 2016;375(26):2519\u201329.","journal-title":"N Engl J Med"},{"issue":"9894","key":"2138_CR112","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/S0140-6736(13)60900-9","volume":"382","author":"N Bhala","year":"2013","unstructured":"Bhala N, et al. Vascular and upper gastrointestinal effects of non-steroidal anti-inflammatory drugs: meta-analyses of individual participant data from randomised trials. Lancet. 2013;382(9894):769\u201379.","journal-title":"Lancet"},{"issue":"4","key":"2138_CR113","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1016\/j.ejim.2015.03.008","volume":"26","author":"P Ungprasert","year":"2015","unstructured":"Ungprasert P, et al. Individual non-steroidal anti-inflammatory drugs and risk of acute kidney injury: a systematic review and meta-analysis of observational studies. Eur J Intern Med. 2015;26(4):285\u201391.","journal-title":"Eur J Intern Med"},{"issue":"10","key":"2138_CR114","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1097\/MEG.0b013e328349de81","volume":"23","author":"X Wang","year":"2011","unstructured":"Wang X, et al. Meta-analysis: cyclooxygenase-2 inhibitors are no better than nonselective nonsteroidal anti-inflammatory drugs with proton pump inhibitors in regard to gastrointestinal adverse events in osteoarthritis and rheumatoid arthritis. Eur J Gastroenterol Hepatol. 2011;23(10):876\u201380.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"2138_CR115","doi-asserted-by":"publisher","first-page":"361","DOI":"10.2147\/JPR.S156938","volume":"11","author":"KA Gwee","year":"2018","unstructured":"Gwee KA, et al. Coprescribing proton-pump inhibitors with nonsteroidal anti-inflammatory drugs: risks versus benefits. J Pain Res. 2018;11:361\u201374.","journal-title":"J Pain Res"},{"key":"2138_CR116","unstructured":"International Osteoporosis Foundation, Nutrition Guidelines. Available from: https:\/\/www.osteoporosis.foundation\/health-professionals\/prevention\/nutrition. Accessed 1 April 2024."},{"key":"2138_CR117","doi-asserted-by":"publisher","first-page":"693","DOI":"10.2147\/IJWH.S409897","volume":"16","author":"B Alabadi","year":"2024","unstructured":"Alabadi B, et al. Nutrition-based support for osteoporosis in postmenopausal women: a review of recent evidence. Int J Womens Health. 2024;16:693\u2013705.","journal-title":"Int J Womens Health"},{"issue":"3","key":"2138_CR118","first-page":"Ra37","volume":"14","author":"P Salari","year":"2008","unstructured":"Salari P, et al. A systematic review of the impact of n-3 fatty acids in bone health and osteoporosis. Med Sci Monit. 2008;14(3):Ra37-44.","journal-title":"Med Sci Monit"},{"key":"2138_CR119","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2020.106124","volume":"100","author":"HA Bischoff-Ferrari","year":"2021","unstructured":"Bischoff-Ferrari HA, et al. DO-HEALTH: Vitamin D3 - Omega-3 - Home exercise - Healthy aging and longevity trial - Design of a multinational clinical trial on healthy aging among European seniors. Contemp Clin Trials. 2021;100: 106124.","journal-title":"Contemp Clin Trials"},{"issue":"1","key":"2138_CR120","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s12905-023-02188-4","volume":"23","author":"M Nouri","year":"2023","unstructured":"Nouri M, et al. How do carbohydrate quality indices influence on bone mass density in postmenopausal women? A case-control study. BMC Womens Health. 2023;23(1):42.","journal-title":"BMC Womens Health"},{"key":"2138_CR121","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.csbj.2019.07.005","volume":"17","author":"I Groenendijk","year":"2019","unstructured":"Groenendijk I, et al. High versus low dietary protein intake and bone health in older adults: a systematic review and meta-analysis. Comput Struct Biotechnol J. 2019;17:1101\u201312.","journal-title":"Comput Struct Biotechnol J"},{"issue":"6","key":"2138_CR122","doi-asserted-by":"publisher","first-page":"1528","DOI":"10.3945\/ajcn.116.145110","volume":"105","author":"MM Shams-White","year":"2017","unstructured":"Shams-White MM, et al. Dietary protein and bone health: a systematic review and meta-analysis from the National Osteoporosis Foundation. Am J Clin Nutr. 2017;105(6):1528\u201343.","journal-title":"Am J Clin Nutr"},{"issue":"6","key":"2138_CR123","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1080\/07315724.2017.1322924","volume":"36","author":"TC Wallace","year":"2017","unstructured":"Wallace TC, Frankenfeld CL. Dietary protein intake above the current RDA and bone health: a systematic review and meta-analysis. J Am Coll Nutr. 2017;36(6):481\u201396.","journal-title":"J Am Coll Nutr"},{"issue":"8","key":"2138_CR124","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1016\/j.jamda.2013.05.021","volume":"14","author":"J Bauer","year":"2013","unstructured":"Bauer J, et al. Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE Study Group. J Am Med Dir Assoc. 2013;14(8):542\u201359.","journal-title":"J Am Med Dir Assoc"},{"key":"2138_CR125","doi-asserted-by":"crossref","unstructured":"Dominguez LJ, et al. Association between serum magnesium and fractures: a systematic review and meta-analysis of observational studies. Nutrients. 2023;15(6).","DOI":"10.3390\/nu15061304"},{"key":"2138_CR126","doi-asserted-by":"publisher","DOI":"10.1016\/j.bone.2021.116233","volume":"154","author":"I Groenendijk","year":"2022","unstructured":"Groenendijk I, et al. Impact of magnesium on bone health in older adults: a systematic review and meta-analysis. Bone. 2022;154: 116233.","journal-title":"Bone"},{"key":"2138_CR127","doi-asserted-by":"crossref","DOI":"10.1155\/2013\/486186","volume":"2013","author":"JP van Wijngaarden","year":"2013","unstructured":"van Wijngaarden JP, et al. Vitamin B12, folate, homocysteine, and bone health in adults and elderly people: a systematic review with meta-analyses. J Nutr Metab. 2013;2013: 486186.","journal-title":"J Nutr Metab"},{"key":"2138_CR128","doi-asserted-by":"crossref","unstructured":"Rondanelli M, et al. Evidence of a positive link between consumption and supplementation of ascorbic acid and bone mineral density. Nutrients. 2021;13(3).","DOI":"10.3390\/nu13031012"},{"issue":"4","key":"2138_CR129","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1007\/s00774-023-01418-x","volume":"41","author":"R Li","year":"2023","unstructured":"Li R, et al. Association between dietary intake of \u03b1-tocopherol and cadmium related osteoporosis in population \u2265 50 years. J Bone Miner Metab. 2023;41(4):501\u201311.","journal-title":"J Bone Miner Metab"},{"issue":"8","key":"2138_CR130","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1007\/s00198-019-04949-0","volume":"30","author":"A Mott","year":"2019","unstructured":"Mott A, et al. Effect of vitamin K on bone mineral density and fractures in adults: an updated systematic review and meta-analysis of randomised controlled trials. Osteoporos Int. 2019;30(8):1543\u201359.","journal-title":"Osteoporos Int"},{"issue":"5","key":"2138_CR131","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1007\/s00774-022-01342-6","volume":"40","author":"M Zhou","year":"2022","unstructured":"Zhou M, et al. Efficacy and safety of vitamin K2 for postmenopausal women with osteoporosis at a long-term follow-up: meta-analysis and systematic review. J Bone Miner Metab. 2022;40(5):763\u201372.","journal-title":"J Bone Miner Metab"},{"key":"2138_CR132","doi-asserted-by":"crossref","unstructured":"Sanchis P, et al. Estimated phytate intake is associated with bone mineral density in Mediterranean postmenopausal women. Nutrients. 2023;15(7).","DOI":"10.3390\/nu15071791"},{"issue":"suppl_2","key":"2138_CR133","doi-asserted-by":"publisher","first-page":"S120","DOI":"10.1093\/advances\/nmy097","volume":"10","author":"P Mat\u00eda-Mart\u00edn","year":"2019","unstructured":"Mat\u00eda-Mart\u00edn P, et al. Effects of milk and dairy products on the prevention of osteoporosis and osteoporotic fractures in europeans and non-hispanic whites from North America: a systematic review and updated meta-analysis. Adv Nutr. 2019;10(suppl_2):S120-s143.","journal-title":"Adv Nutr"},{"issue":"10","key":"2138_CR134","doi-asserted-by":"publisher","first-page":"1722","DOI":"10.1080\/10408398.2019.1590800","volume":"60","author":"H Malmir","year":"2020","unstructured":"Malmir H, Larijani B, Esmaillzadeh A. Consumption of milk and dairy products and risk of osteoporosis and hip fracture: a systematic review and Meta-analysis. Crit Rev Food Sci Nutr. 2020;60(10):1722\u201337.","journal-title":"Crit Rev Food Sci Nutr"},{"issue":"1","key":"2138_CR135","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1007\/s40520-024-02696-9","volume":"36","author":"M Rondanelli","year":"2024","unstructured":"Rondanelli M, et al. Evaluating adherence, tolerability and safety of oral calcium citrate in elderly osteopenic subjects: a real-life non-interventional, prospective, multicenter study. Aging Clin Exp Res. 2024;36(1):38.","journal-title":"Aging Clin Exp Res"},{"issue":"1","key":"2138_CR136","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40520-024-02721-x","volume":"36","author":"R Rizzoli","year":"2024","unstructured":"Rizzoli R, Biver E. Role of fermented dairy products in the health benefits of a mediterranean diet. Aging Clin Exp Res. 2024;36(1):75.","journal-title":"Aging Clin Exp Res"},{"issue":"1","key":"2138_CR137","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1007\/s40520-021-01970-4","volume":"34","author":"R Rizzoli","year":"2022","unstructured":"Rizzoli R. Dairy products and bone health. Aging Clin Exp Res. 2022;34(1):9\u201324.","journal-title":"Aging Clin Exp Res"},{"issue":"6","key":"2138_CR138","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s40520-019-01131-8","volume":"31","author":"R Rizzoli","year":"2019","unstructured":"Rizzoli R. Nutritional influence on bone: role of gut microbiota. Aging Clin Exp Res. 2019;31(6):743\u201351.","journal-title":"Aging Clin Exp Res"},{"issue":"1","key":"2138_CR139","first-page":"109","volume":"97","author":"Y Somekawa","year":"2001","unstructured":"Somekawa Y, et al. Soy intake related to menopausal symptoms, serum lipids, and bone mineral density in postmenopausal Japanese women. Obstet Gynecol. 2001;97(1):109\u201315.","journal-title":"Obstet Gynecol"},{"issue":"1","key":"2138_CR140","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1007\/s00774-023-01479-y","volume":"42","author":"F Zhou","year":"2024","unstructured":"Zhou F, et al. Tea consumption and risk of bone health: an updated systematic review and meta-analysis. J Bone Miner Metab. 2024;42(1):99\u2013114.","journal-title":"J Bone Miner Metab"},{"key":"2138_CR141","doi-asserted-by":"crossref","unstructured":"Morales-Ivorra I, et al. Osteoarthritis and the Mediterranean diet: a systematic review. Nutrients, 2018;10(8).","DOI":"10.3390\/nu10081030"},{"issue":"4","key":"2138_CR142","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1007\/s40520-020-01515-1","volume":"32","author":"NR Fuggle","year":"2020","unstructured":"Fuggle NR, et al. Alternative and complementary therapies in osteoarthritis and cartilage repair. Aging Clin Exp Res. 2020;32(4):547\u201360.","journal-title":"Aging Clin Exp Res"},{"key":"2138_CR143","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2019.100946","volume":"55","author":"E Biver","year":"2019","unstructured":"Biver E, et al. Gut microbiota and osteoarthritis management: An expert consensus of the European society for clinical and economic aspects of osteoporosis, osteoarthritis and musculoskeletal diseases (ESCEO). Ageing Res Rev. 2019;55:100946.","journal-title":"Ageing Res Rev"},{"issue":"6","key":"2138_CR144","doi-asserted-by":"publisher","first-page":"e247","DOI":"10.1016\/S2666-7568(23)00057-0","volume":"4","author":"PL Valenzuela","year":"2023","unstructured":"Valenzuela PL, et al. Effects of physical exercise on physical function in older adults in residential care: a systematic review and network meta-analysis of randomised controlled trials. Lancet Healthy Longev. 2023;4(6):e247\u201356.","journal-title":"Lancet Healthy Longev"},{"key":"2138_CR145","unstructured":"WHO guidelines on physical activity and sedentary behaviour. Geneva: World Health Organization. 2020."},{"issue":"4","key":"2138_CR146","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1002\/art.20968","volume":"52","author":"DD Dunlop","year":"2005","unstructured":"Dunlop DD, et al. Risk factors for functional decline in older adults with arthritis. Arthritis Rheum. 2005;52(4):1274\u201382.","journal-title":"Arthritis Rheum"},{"issue":"5","key":"2138_CR147","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1016\/j.amepre.2018.12.017","volume":"56","author":"DD Dunlop","year":"2019","unstructured":"Dunlop DD, et al. One hour a week: moving to prevent disability in adults with lower extremity joint symptoms. Am J Prev Med. 2019;56(5):664\u201372.","journal-title":"Am J Prev Med"},{"issue":"5","key":"2138_CR148","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/j.semarthrit.2017.10.005","volume":"47","author":"J Song","year":"2018","unstructured":"Song J, et al. Relationship of knee pain to time in moderate and light physical activities: data from Osteoarthritis Initiative. Semin Arthritis Rheum. 2018;47(5):683\u20138.","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"2138_CR149","doi-asserted-by":"publisher","first-page":"2485","DOI":"10.1016\/j.apmr.2017.06.004","volume":"98","author":"D Pinto","year":"2017","unstructured":"Pinto D, et al. Association between sedentary time and quality of life from the osteoarthritis initiative: who might benefit most from treatment? Arch Phys Med Rehabil. 2017;98(12):2485\u201390.","journal-title":"Arch Phys Med Rehabil"},{"issue":"11","key":"2138_CR150","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1007\/s10654-017-0312-5","volume":"32","author":"YT Lagerros","year":"2017","unstructured":"Lagerros YT, et al. Physical activity and the risk of hip fracture in the elderly: a prospective cohort study. Eur J Epidemiol. 2017;32(11):983\u201391.","journal-title":"Eur J Epidemiol"},{"issue":"10","key":"2138_CR151","first-page":"939","volume":"102","author":"LK Lau","year":"2023","unstructured":"Lau LK, et al. Effects of exercise interventions on physical performance and activities of daily living in oldest-old and frail older adults: a review of the literature. Am J Phys Med Rehabil. 2023;102(10):939\u201349.","journal-title":"Am J Phys Med Rehabil"},{"key":"2138_CR152","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1016\/j.physio.2019.01.013","volume":"106","author":"J Knoop","year":"2020","unstructured":"Knoop J, et al. Is a model of stratified exercise therapy by physical therapists in primary care feasible in patients with knee osteoarthritis?: a mixed methods study. Physiotherapy. 2020;106:101\u201310.","journal-title":"Physiotherapy"},{"key":"2138_CR153","doi-asserted-by":"crossref","unstructured":"Kemmler W, et al. Effects of high intensity dynamic resistance exercise and whey protein supplements on osteosarcopenia in older men with low bone and muscle mass. final results of the randomized controlled FrOST Study. Nutrients, 2020;12(8).","DOI":"10.3390\/nu12082341"},{"issue":"12","key":"2138_CR154","first-page":"A4554","volume":"59","author":"ST Skou","year":"2012","unstructured":"Skou ST, et al. Group education and exercise is feasible in knee and hip osteoarthritis. Dan Med J. 2012;59(12):A4554.","journal-title":"Dan Med J"},{"issue":"3","key":"2138_CR155","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1017\/S0266462320000215","volume":"36","author":"B O'Rourke","year":"2020","unstructured":"O\u2019Rourke B, Oortwijn W, Schuller T. The new definition of health technology assessment: a milestone in international collaboration. Int J Technol Assess Health Care. 2020;36(3):187\u201390.","journal-title":"Int J Technol Assess Health Care"},{"issue":"1","key":"2138_CR156","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1017\/S0266462319000825","volume":"36","author":"B O'Rourke","year":"2020","unstructured":"O\u2019Rourke B, et al. The \u201cTop 10\u201d challenges for health technology assessment: INAHTA viewpoint. Int J Technol Assess Health Care. 2020;36(1):1\u20134.","journal-title":"Int J Technol Assess Health Care"},{"issue":"4","key":"2138_CR157","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/s40273-022-01239-2","volume":"41","author":"N Li","year":"2023","unstructured":"Li N, et al. Cost effectiveness analyses of interventions for osteoporosis in men: a systematic literature review. Pharmacoeconomics. 2023;41(4):363\u201391.","journal-title":"Pharmacoeconomics"},{"issue":"2","key":"2138_CR158","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s40273-020-00965-9","volume":"39","author":"N Li","year":"2021","unstructured":"Li N, et al. An updated systematic review of cost-effectiveness analyses of drugs for osteoporosis. Pharmacoeconomics. 2021;39(2):181\u2013209.","journal-title":"Pharmacoeconomics"},{"issue":"4","key":"2138_CR159","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1007\/s00198-022-06626-1","volume":"34","author":"G Yu","year":"2023","unstructured":"Yu G, et al. A systematic review of cost-effectiveness analyses of sequential treatment for osteoporosis. Osteoporos Int. 2023;34(4):641\u201358.","journal-title":"Osteoporos Int"},{"issue":"1","key":"2138_CR160","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1007\/s40520-023-02682-7","volume":"36","author":"M Hiligsmann","year":"2024","unstructured":"Hiligsmann M, et al. Comparison of the cost-effectiveness of sequential treatment with abaloparatide in US men and women at very high risk of fractures. Aging Clin Exp Res. 2024;36(1):14.","journal-title":"Aging Clin Exp Res"},{"issue":"7","key":"2138_CR161","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1007\/s40273-023-01270-x","volume":"41","author":"M Hiligsmann","year":"2023","unstructured":"Hiligsmann M, et al. Cost-effectiveness of sequential abaloparatide\/alendronate in men at high risk of fractures in the United States. Pharmacoeconomics. 2023;41(7):819\u201330.","journal-title":"Pharmacoeconomics"},{"issue":"3","key":"2138_CR162","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/j.semarthrit.2013.07.003","volume":"43","author":"M Hiligsmann","year":"2013","unstructured":"Hiligsmann M, et al. Health economics in the field of osteoarthritis: an expert\u2019s consensus paper from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Semin Arthritis Rheum. 2013;43(3):303\u201313.","journal-title":"Semin Arthritis Rheum"},{"issue":"3","key":"2138_CR163","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1007\/s40258-022-00717-0","volume":"20","author":"J Shi","year":"2022","unstructured":"Shi J, et al. Cost effectiveness of pharmacological management for osteoarthritis: a systematic review. Appl Health Econ Health Policy. 2022;20(3):351\u201370.","journal-title":"Appl Health Econ Health Policy"},{"issue":"4","key":"2138_CR164","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1016\/j.joca.2020.10.002","volume":"29","author":"DR Mazzei","year":"2021","unstructured":"Mazzei DR, et al. Are education, exercise and diet interventions a cost-effective treatment to manage hip and knee osteoarthritis? A systematic review. Osteoarthr Cartil. 2021;29(4):456\u201370.","journal-title":"Osteoarthr Cartil"},{"key":"2138_CR165","doi-asserted-by":"crossref","unstructured":"Vo NX, et al. Cost-Effectiveness of glucosamine in osteoarthritis treatment: a systematic review. Healthcare (Basel). 2023;11(16).","DOI":"10.3390\/healthcare11162340"},{"issue":"5","key":"2138_CR166","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1016\/j.arth.2017.11.063","volume":"33","author":"ST Kunkel","year":"2018","unstructured":"Kunkel ST, et al. The Cost-effectiveness of total hip arthroplasty in patients 80 years of age and older. J Arthroplasty. 2018;33(5):1359\u201367.","journal-title":"J Arthroplasty"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02138-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-024-02138-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-024-02138-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,10]],"date-time":"2025-03-10T09:33:51Z","timestamp":1741599231000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-024-02138-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,19]]},"references-count":166,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,3]]}},"alternative-id":["2138"],"URL":"https:\/\/doi.org\/10.1007\/s40265-024-02138-w","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,19]]},"assertion":[{"value":"1 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The ESCEO working group was funded by the ESCEO. The ESCEO receives unrestricted educational grants to support its educational and scientific activities from non-governmental organisations, not-for-profit organisations, non-commercial, or corporate partners. The choice of topics, participants, content, and agenda of the working groups as well as the writing, editing, submission, and reviewing of the manuscript are the sole responsibility of the ESCEO, without any influence from third parties.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"NA-D, MA, CB, ABvB, NB, EC, MC, AC, PGC, EC, PD\u2019A, BD-H, J-MK, SM, RM, EM, ODM, DP, MCPY, RPR\u00a0and JAK, and\u00a0have no competing interests to declare with respect to this manuscript. NF has received honoraria and speaker fees from Viatris and UCB. RRi has received fees for advisory board participation or lectures from Abiogen, Effryx, and Theramex.\u00a0NCH has received personal fees, consultancy, lecture fees and\/or honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, UCB, Kyowa Kirin, Servier, Shire, Consilient Healthcare, Theramex and Internis Pharma. OB has received consulting or lecture fees from Amgen, Aptissen, Biophytis, IBSA, Mylan, Novartis, Nutricia, Orifarm, Sanofi, UCB, and Viatris. BC has received personal fees, consultancy fees, lecture fees, and honoraria from Alexion, Amgen, Expanscience, Kyowa-Kirin, MSD, Novartis,Theramex, UCB, and Viatris. AC-J has received honoraria for teaching activities from Abbott Nutrition, Fresenius Kabi, Nestl\u00e9 Health Care, and Nutricia Danone. EMD has received consultancy honoraria and speaker fees from UCB, Pfizer, Viatris, and Lilly. MH has received research grants (paid to institution) from Radius Health and Angelini Pharma and lecture fees from IBSA (paid to institution) and Mylan Pharmaceuticals and was grant advisor for Pfizer (paid to institution). YR has received support from CHU Toulouse, University Paul Sabatier, and INSERM CERPOP1295 (employee); is a shareholder of SARQOL SPRL, a spin-off of the University of Liege; and has received consultancy fees from Longeveron and Biophytis and honoraria for lectures from Pfizer. NV has received personal fees from MYLAN, FIDIA, IBSA, Viatris, and Nestl\u00e8. AL is a member of the Scientific Advice Working Party at the European Medicines Agency and has no conflicting interests to declare. EB-I is a member of the CHMP, SAWP, CNSWP, PCWP, and ETF (European Medicines Agency) and has no conflicting interests to declare. FC has no competing interests with respect to this manuscript. CT is a member of the CHMP, PRAC, and MWP (European Medicines Agency) and has no conflicting interests to declare. MMR is a member of the SAWP and CNSWP (European Medicines Agency) and has no conflicting interests to declare. The views expressed in this article are the personal views of the authors and may not be understood or quoted as being made on behalf of or reflecting the position of any employing organisations or the regulatory agencies by which the authors are employed or affiliated, the European Medicines Agency (EMA), or one of its committees or working parties. CC has received personal fees, consultancy, lecture fees and\/or honoraria from ABBH, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier and Takeda. JYR has received consulting fees or paid advisory boards for IBSA-Genevrier, Mylan, Radius Health, Pierre Fabre, Faes Pharma, Rejuvenate Biomed, Samumed, Teva, Theramex, Pfizer, Mithra Pharmaceuticals, lecture fees when speaking at the invitation of the sponsor for IBSA-Genevrier, Mylan, Cniel, Dairy Research Council (DRC), Nutricia, Danone, Agnovos and grant support from IBSA-Genevrier, Mylan, Cniel, Radius Health, TRB.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and material"}},{"value":"This narrative article contains no original data, so issues of ethics, informed consent, and patient confidentiality do not apply.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"All authors contributed to the discussion of the subject matter. NF, AL, RR, JYR, and NCH wrote the draft\u00a0manuscript. All authors reviewed and commented on the manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}